A compact, instantly brandable five-letter domain that fuses the two most commercially charged fragments in technology and health today — AI and vax. This report examines the name’s structure, its commercial reach and a reasoned market valuation.
The strength of aivax lies in how cleanly it reads as a single, coined brand while carrying two recognisable signals. It is short enough to type without error, easy to say aloud, and free of hyphens or numerals — the hallmarks of a name that travels well across a logo, an app icon and a spoken advertisement.
The defining label of the decade. “AI” immediately frames a venture as modern, intelligent and forward-looking — the single most sought-after prefix in domain investing today.
Reads as “vaccine” in health and biotech, yet doubles as a metaphor for protection and immunity — opening the door to security, resilience and defensive-technology branding.
Few names flex across this many high-value sectors. Each of the directions below is a credible, ready-made foundation for a product, a company or a campaign.
An intelligent platform for vaccination scheduling, immunisation records, patient triage or public-health analytics for clinics, pharmacies and the NHS supply chain.
“Vaccinate” your systems — an AI-driven antivirus, threat-detection or resilience product that turns the immunity metaphor into a security brand.
AI-accelerated vaccine and drug discovery, clinical-trial modelling or molecular research — a natural fit for a life-sciences start-up or lab.
A clean, coined identity for any AI software house, agency or app where the founders want a name that simply sounds like the future.
The following ratings benchmark aivax.co.uk against the attributes that drive domain value.
| Attribute | Rating |
|---|---|
| Brandability | Excellent |
| Memorability & recall | Excellent |
| Length & type-in ease | Excellent |
| Sector relevance (AI / health) | Very strong |
| Commercial versatility | Very strong |
| Extension trust (.co.uk) | Strong |
The valuation below reflects current demand for short, brandable AI-prefixed names, the dual-sector reach of the “vax” root, comparable sales of five-letter coined domains, and the established trust of the .co.uk extension within the UK market. It is presented as a fair open-market figure for an end-user acquirer rather than a wholesale or liquidation price.